Panel: In Abandoning Product, Appellant Lost Standing In Patent Appeal

Mealey's (February 8, 2019, 2:25 PM EST) -- WASHINGTON, D.C. — Momenta Pharmaceuticals Inc. forfeited any legally protected interest in the validity of a Bristol-Myers Squibb Co. (BMS) patent when it abandoned development of a proposed biosimilar drug, the Federal Circuit U.S. Court of Appeals concluded Feb. 7 (Momenta Pharmaceuticals Inc. v. Bristol-Myers Squibb Co., No. 17-1694, Fed. Cir., 2019 U.S. App. LEXIS 3786)....